ventipulmin
boehringer ingelheim vetmedica gmbh - clenbuterolo cloridrato - clenbuterolo cloridrato - 0.03 milligrammo (i), clenbuterolo cloridrato - 0.03 mg - clenbuterol
dilaterol sciroppo per cavalli
le vet beheer b.v. - clenbuterolo cloridrato - clenbuterolo cloridrato - 0.03 milligrammo (i), clenbuterolo cloridrato - 0.03 mg - clenbuterol
monores
valeas spa industria chimica e farmaceutica - clenbuterolo - clenbuterolo
spiropent
boehringer ingelheim italia s.p.a. - clenbuterolo - clenbuterolo
broncodil
epifarma s.r.l - clenbuterolo - clenbuterolo
clenasma
biomedica foscama industria chimico farmaceutica s.p.a. - clenbuterolo - clenbuterolo
prontovent
salus researches s.p.a. - clenbuterolo - clenbuterolo
aservo equihaler
boehringer ingelheim vetmedica gmbh - ciclesonide - sistema respiratorio, altri farmaci per le malattie respiratorie ostruttive, inalanti - cavalli - per la riduzione dei segni clinici di grave equina asma (precedentemente noto come ricorrenti di ostruzione delle vie aeree – (rao), pascolo estivo associato ricorrenti di ostruzione delle vie aeree – (spa-rao)).
terazosina hexal
sandoz s.p.a. - terazosina - terazosina
sitagliptin / metformin hydrochloride sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.